## Abstract Botulinum toxin is now widely used in the treatment of severla hyperkinetic movement disorders. To evaluate its efficacy in treating muscle cramping syndromes, we studied clinical and neurophysiological variables before and after botulinum toxin injections into calf muscles and small fl
Serial neurophysiological studies of intramuscular botulinum-A toxin in humans
β Scribed by John A. Hamjian; Francis O. Walker
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 706 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
β¦ Synopsis
To characterize the time course of intramuscular botulinum toxininduced paresis, we serially performed electrophysiological measurements and recorded the sonographic size of an extensor digitorum brevis (EDB) muscle in 10 human subjects before and after injecting the EDB with 10 units of botulinum-A toxin. All EDB CMAPs decreased within 48 h, with peak decline at day 21 (8.3 f 3.1 mV to 3.0 f 0.9 mV). Decline of mean rectified voltage during maximal voluntary contraction of the EDB paralleled the change in CMAP amplitude. Average decrements to 2-Hz repetitive stimulation never exceeded 6% (day 42) and exercise failed to facilitate significantly CMAP amplitude. Atrophy peaked at day 42. The F-wave to M-wave ratio increased at day 2; silent periods did not change. Our findings confirm a primary peripheral action of the toxin, but a superimposed, transient central effect of the drug cannot be excluded. Intramuscular injections into EDB provide a useful model for studying chemodenervation effects.
π SIMILAR VOLUMES
## Abstract Botulinum toxin A (BoNTβA) is a potent biological toxin widely used for the management of skeletal muscle spasticity or dynamic joint contracture. Intramuscular injection of BoNTβA causes muscle denervation, paresis, and atrophy. This clinical effect of botulinum toxin A lasts 3 to 6 mo
## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, openβlabel, doseβescalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses